Skip to main content
GameRevenueData

Developer

NedoStudio Games: Revenue & Sales Estimates

Revenue estimates for the 10 Steam games developed by NedoStudio, ranked by estimated net revenue. Available estimated lifetime net (USD): $88.7K.

Catalog Est. Lifetime Net (USD)

$88.7K

Estimates for 9 of 10 tracked games

Tracked games

10

Top Earner

Ablepsia

$20.9K

Coverage: 10 tracked titles; 9 with net estimates; 1 without. 5 have dedicated profiles. Missing estimates are excluded from the aggregate, not treated as known zero revenue.

Role: Developer. These are lifetime estimates for games credited to NedoStudio; they are not company earnings, profit, or contractual receipts. Credits may omit co-development or historical publishing arrangements. Developer and publisher identities are not merged by matching names.

Recorded release dates: 2017-07-11–2021-01-05 (may include announced dates).

Largest title accounts for 23.6% of available estimated net revenue. Coverage gaps can change this share.

Showing 1–10 of the top 10 displayed entries, from 10 tracked titles. Figures include only available estimates. Search the full catalog .

Rows 1–10 · Page 1 of 1

# Game Est. lifetime net (USD) Positive reviews (raw) Release
1 Ablepsia $20.9K 55%Mixed (185) Sep 27, 2017
2 illie $18.4K 82%Positive (159) Nov 6, 2017
3 Gelu $16.2K 81%Positive (140) Jul 11, 2017
4 Qvabllock $13.6K 81%Positive (118) Apr 30, 2018
5 Dupio $5.4K 56%Mixed (48) Mar 6, 2018
6 Freezeer $4.7K 70%Positive (185) Jun 21, 2018
7 Through Blocks $3.9K 32%Negative (44) May 6, 2019
8 DarkLast $3.8K 28%Negative (46) Feb 15, 2018
9 Until the last $1.7K 41%Mixed (27) Sep 11, 2017
10 Super Hyperspace Avenger 100%Positive (3) Jan 5, 2021

Get real-time dashboards, historical trends, and AI-powered analysis

Explore on PlayRev(opens in new tab)

Revenue and sales estimates are based on the Boxleiter method using publicly available data including Steam review counts, pricing history, and statistical modeling. Actual revenue may differ significantly. These figures are provided for informational purposes only and should not be used for financial decisions. Read the full methodology.